ORTX - Orchard Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

263.1M

Cash

150.7M

Avg Qtr Burn

-21.84M

Short % of Float

0.43%

Insider Ownership

13.27%

Institutional Own.

37.89%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Libmeldy / OTL-200 (ex vivo autologous gene therapy) Details Rare diseases, Rare genetic disease, Metachromatic leukodystrophy Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Sanfilippo Syndrome, Mucopolysaccharidosis type IIIA	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-103 (ex vivo autologous gene therapy) Details X-Linked severe combined immunodeficiency, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.